false 0001680581 0001680581 2025-01-13 2025-01-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2025

 

 

Fulcrum Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38978   47-4839948

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

26 Landsdowne Street  
Cambridge, Massachusetts   02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 651-8851

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common stock, par value $0.001 per share   FULC   Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 2.02

Results of Operations and Financial Condition

Although it has not yet finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2024, Fulcrum Therapeutics, Inc., or Fulcrum, published an updated corporate presentation on its Website on January 13, 2025, which is attached as Exhibit 99.1 hereto, announcing that it expects to report that it had approximately $240 million of cash, cash equivalents and marketable securities as of December 31, 2024.

The information contained in this Item 2.02 of, and in Exhibit 99.1 attached to, this current report on Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of Fulcrum’s financial condition as of December 31, 2024. The audit of Fulcrum’s consolidated financial statements for the year ended December 31, 2024 is ongoing and could result in changes to the information set forth above.

The information in this Item 2.02, and in Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


Item 7.01

Regulation FD Disclosure.

On January 13, 2025, Fulcrum published an updated corporate presentation on its website. Fulcrum is furnishing as Exhibit 99.1 to this current report on Form 8-K a copy of the slides from such presentation, which updated information is incorporated by reference herein.

The information in this Item 2.02, and in Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits

 

(d)

Exhibits

The following exhibit is furnished herewith:

 

Exhibit

No.

   Description
99.1    Corporate Presentation dated January 13, 2025.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      FULCRUM THERAPEUTICS, INC.
Date: January 13, 2025     By:  

/s/ Alex C. Sapir

      Name: Alex C. Sapir
      Title: President and Chief Executive Officer